SHSaba Hasanzadeh

Saba Hasanzadeh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Saba Hasanzadeh has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effectiveness of Low-Level and High-level Laser Therapy for Rotator Cuff–Related Shoulder Disorders: A Systematic Review and Meta-Analysis

    by Sahar Dadkhahfar, Maryam Abbasian, Saba Hasanzadeh, Parsa Omidvar, Seyed Mohammadmisagh Moteshakereh, Hooshmand Zarei, Mahsa Nikkhoo, Mohammadreza Abbasian

    Introduction: While photobiomodulation and high-power lasers are common for rotator cuff-related shoulder pain, evidence interpretation is hindered by inconsistent dosimetry and clinical findings. This systematic review and meta-analysis evaluate the effects of low-level (LLLT) and high-level laser therapy (HLLT) on pain, range of motion (ROM), and shoulder function. Methods: This PROSPERO-registered review included randomized controlled trials comparing LLLT or HLLT against sham, no treatment, or conventional care. Two reviewers independently conducted screening, data extraction, and risk-of-bias assessment. Continuous outcomes were synthesized using random-effects models, supplemented by subgroup analyses (LLLT vs. HLLT; laser vs. laser plus exercise) and sensitivity analyses to address heterogeneity. Results: Twenty-three trials (wavelengths 805–1064 nm) were included. Pooled analysis showed that laser therapy significantly reduced overall pain (VAS: MD −5.22; 95% CI −7.56 to −2.88; P<0.001 P<0.001 P<0.001), though improvements in pain at rest, during movement, and at night were not statistically significant. After excluding outliers, modest improvements were noted in active internal rotation (MD 1.14; 95% CI 0.19–2.09; P<0.001 P<0.001 P<0.001) and passive external rotation (MD −1.33; 95% CI −1.92 to −0.73; P<0.001 P<0.001 P<0.001). Subgroup analysis indicated that HLLT yielded superior active-abduction outcomes compared to LLLT (P=0.016 P=0.016 P=0.016). Certainty was limited by heterogeneity, small sample sizes, inconsistent dosimetry, and short follow-up. Conclusion: Laser therapy provides modest, reproducible analgesic benefits, and selective ROM improvements, particularly when HLLT is combined with exercise. Given the limited functional gains and reporting inconsistencies, lasers should be used as an adjunct to structured rehabilitation rather than a standalone treatment. Future trials require standardized dosing and longer follow-ups.

  • Open Access

    Hyalase in Dermatology: Applications Beyond Filler Management

    by Saba Hasanzadeh, Parisa Farokh, Golsa Sadat Hosseini, Maryam Abbasian, Ifa Etesami, Shirin Zaresharifi, Sahar Dadkhahfar

    Background: Hyaluronic acid (HA) is a key extracellular matrix component in the skin. Hyaluronidase is an enzyme that breaks down HA into monosaccharides. The FDA has approved this enzyme for hypodermoclysis, drug absorption enhancement, and subcutaneous urography. The most common application of this enzyme is the dissolution of HA fillers. Aim: This study aimed to explore the various applications of hyaluronidase beyond its common medical uses. Moreover, we illustrate the mechanism by which this enzyme is helpful in conditions such as drug extravasation, scleroderma, scleromyxedema, and keloids. Methods: A comprehensive review of hyaluronidase applications in medicine, with a specific focus on dermatology, was conducted using PubMed/MEDLINE, the Cochrane Library, and Embase. The conditions under which hyaluronidase was applied are discussed, and the protocols used for each condition are evaluated and summarized. Results: Hyaluronidase improves tissue permeability and enhances drug delivery. Therefore, it is beneficial for treating keloids, managing pain, and enhancing the distribution of chemotherapeutic agents within tumors. It is also useful for reducing fibrosis in scleroderma, scleromyxedema, and chronic GVHD. Hyaluronidase is considered a safe drug, and its adverse effects are infrequent. Conclusion: Hyaluronidase has the potential to be useful for various medical and dermatological conditions. Further research is required to fill existing gaps and establish standardized usage protocols.


  • The efficacy and safety of relatlimab/nivolumab combination therapy in patients with advanced melanoma: a systematic review

    by Saba Hasanzadeh, Parisa Farokh, Fatemeh Vazifeh, Golsa Sadat Hosseini, Leila Rezaei, Mozhgan Ghaedrahmati, Zahra Razaghi, Mostafa Rezaei Tavirani, Reza M Robati

    Finding a treatment approach with high efficacy and minimal adverse reactions for advanced melanoma is still challenging. This study aimed to review and summarize available evidence regarding the effectiveness of the newly FDA-approved combination therapy of Relatmlimab and Nivolumab in patients with advanced melanoma and its comorbidities. We searched MEDLINE, EMBASE, and Cochrane Library for studies published in any language till 29/11/2023. We used the following Mesh and Emtree words, “melanoma” AND “relatlimab” AND “nivolumab”. We screened 398 articles and included two single-arm clinical trials (N = 2) and one randomized clinical trial (RCT) (N = 1). In conclusion, The relatlimab/nivolumab combination therapy showed promising results for advanced melanoma patients. However, further research and longer follow-up periods are needed to compare it with previous treatments and validate its long-term effectiveness and safety.


  • Open Access

    A rare case of cicatricial pemphigoid confined to the scalp with associated photodamage

    by Nasim Niknezhad, Nushin Golchin, Saba Hasanzadeh, Fariba Ghalamkarpour

    Key Clinical Message: We present a case of Brunsting‐Perry characterized as an erythematous erosive plaque on photodamaged scalp skin, flaring after a recent prolonged sun exposure. Subsequent progression with blister formation led to the correct diagnosis, highlighting the need to consider cicatricial pemphigoid in eroded lesions without blisters, particularly on photodamaged skin.


  • Open Access

    Improvement of plantar hyperhidrosis following the treatment of primary palmar hyperhidrosis with botulinum toxin injection

    by Fatemeh Moieneddin, Saba Hasanzadeh, Martin Kassir, Reza M. Robati


  • Open Access

    Presentation of vitiligo in a case of COVID ‐19 infection concomitant with receiving remdesivir

    by Farideh Beyki, Saba Hasanzadeh, Fariba Ghalamkarpour

    Key Clinical Message: The occurrence of vitiligo following COVID‐19 infection and vaccination is well‐documented. The mitochondrial dysfunction of melanocytes in vitiligo and the potential impact of RDV on mitochondria raise concerns about RDV possibly causing vitiligo.

  • Open Access

    Morphea‐like discoid lupus erythematosus in a patient with a history of polyacrylamide gel injection: A case report

    by Saba Hasanzadeh, Mahsa Babaie, Azadeh Rakhshan, Sahar Dadkhahfar

    Background: Discoid lupus erythematosus (DLE) is an autoimmune disease with multifactor etiology which develops in genetically susceptible patients. Rarely, DLE lesions can mimic other connective tissue disorders such as morphea. The growing application of soft tissue fillers is associated with increasing complications. Some substances used for soft tissue augmentation such as silicon implants may trigger lupus erythematosus diseases. Case report: Here we report a case of morphea‐like discoid lupus erythematosus developed several years after polyacrylamide dermal filler (PAAG) injection for facial rejuvenation. Conclusion: As noninvasive procedures like dermal filler injections are increasing worldwide, physicians may consider the long‐term probable side effects of these compounds.

  • Open Access

    Botulinium toxin applications in the lower face and neck: A comprehensive review

    by Martin Kassir, Mahsa Babaei, Saba Hasanzadeh, Mostafa Rezaei Tavirani, Zahra Razzaghi, Reza M. Robati

    Background: Botulinum toxin has been widely and mainly used for the treatment of conditions affecting the upper and middle face; however, recent efforts have expanded the indications of botulinum toxin injection to the lower face and neck areas for cosmetic and medical purposes.Aims: We have reviewed the latest updates on using botulinum toxin in the lower face and neck focusing on cosmetic purposes and have discussed the existing concerns as well as the adverse sequelae of these newer indications.Patients/Methods: A comprehensive literature search was performed using the following keywords [[botulinum] AND [[Toxin] OR [Neurotoxin]]] AND [[Lower AND Face] AND/OR [Neck]] within the main databases including Web of Science, PubMed, Embase and gray literature on and before February 2023. The data were screened using titles and abstracts and those relevant to the topic were included in the paper.Results: Botulinum toxin injection has considerable cosmetic and therapeutic effect on facial contouring, masseteric hypertrophy, lower face and neck scars, gummy smile, drooping lip corner and even skin rejuvenation.Conclusion: BNT injection has been widely used for the treatment of different medical and cosmetic purposes. Low rates of side effects, which were self‐limited in most cases, have been reported in the literature, making BNT a safe therapeutic medication in most cases. However, regulatory status needs to be updated and more accurately revised in many countries and more comprehensive research is required to address the existing gaps in this area including the site, dosage, and method of injection in each case.


  • Open Access

    COVID-19 clinical characteristics, and sex-specific risk of mortality: Systematic Review and Meta-analysis

    by Mohammad Javad Nasiri, Sara Haddadi, Azin Tahvildari, Yeganeh Farsi, Mahta Arbabi, Saba Hasanzadeh, Parnian Jamshidi, Mukunthan Murthi, Mehdi Mirsaeidi

    Objectives: The rapidly evolving coronavirus disease 2019 (COVID-19), was declared a pandemic by the World Health Organization on March 11, 2020. It was first detected in the city of Wuhan in China and has spread globally resulting in substantial health and economic crisis in many countries. Observational studies have partially identified the different aspects of this disease. Up to this date, no comprehensive systematic review for the clinical, laboratory, epidemiologic and mortality findings has been published. We conducted this systematic review and meta-analysis for a better understanding of COVID-19. Methods: We reviewed the scientific literature published from January 1, 2019 to March 3, 2020. Statistical analyses were performed with STATA (version 14, IC; Stata Corporation, College Station, TX, USA). The pooled frequency with 95% confidence intervals (CI) was assessed using random effect model. Publication bias was assessed and p <0.05 was considered a statistically significant publication bias. Results: Out of 1102 studies, 32 satisfied the inclusion criteria. A total of 4789 patients with a mean age of 49 years were evaluated. Fever (83.0%, CI 77.5 to 87.6), cough (65.2%, CI 58.6 to 71.2) and myalgia/fatigue (34.7, CI 26.0 to 44.4) were the most common symptoms. The most prevalent comorbidities were hypertension (18.5 %, CI 12.7 to 24.4) and Cardiovascular disease (14.9 %, CI 6.0 to 23.8). Among the laboratory abnormalities, elevated C-Reactive Protein (CRP) (72.0% (CI 54.3 to 84.6) and lymphopenia (50.1%, CI 38.0 to 62.4) were the most common findings. Bilateral ground-glass opacities (66.0%, CI 51.1 to 78.0) was the most common CT-Scan presentation. Pooled mortality rate was 6.6%, with males having significantly higher mortality compared to females (OR 3.4; 95% CI 1.2 to 9.1, P = 0.01). Conclusion: COVID-19 commonly presented with a progressive course of cough and fever with more than half of hospitalized patients showing leukopenia or a high CRP on their laboratory findings. Mortality associated with COVID19 was higher than that reported in studies in China with Males having a 3-fold higher risk of mortality in COVID19 compared to females.